How much bacteriostatic water with CJC-1295 No DAC?
Most research-handling protocols use 2 mL of bacteriostatic water per 10 mg CJC-1295 No DAC vial, yielding a 5 mg/mL working concentration. The short half-life supports daily or twice-daily dosing in the 100-200 mcg per-draw range, which 5 mg/mL accommodates at 2-4 syringe units.
What the research literature says
CJC-1295 No DAC (modified GRF 1-29) has a ~30-minute plasma half-life supporting pulsatile GH release at each dose. Research-protocol dosing typically uses 100-200 mcg per draw on a daily or twice-daily subcutaneous schedule. The compound’s pharmacology was characterised across the Jetté identification paper (PMID 15817669) and the Teichman clinical-pharmacology work in healthy adults (PMID 16352683) — both anchored to the DAC variant but informative for the No DAC dose-titration framework.
For a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg/mL): a 100 mcg dose draws 2 units on an insulin syringe; 200 mcg draws 4 units; 300 mcg draws 6 units. With 1 mL fill (10 mg/mL), the per-draw volumes halve — 100 mcg becomes 1 unit, which sits at the precision floor for the typical 1 mL insulin syringe. The 2 mL fill is the typical pick for protocols anchored to the 100 mcg dose tier.
The combined CJC-1295 + Ipamorelin Blend format uses a similar reconstitution math but distributes the 10 mg total across both component compounds at 5 mg each — the per-draw math accounts for both compounds delivered together in a single syringe draw.
Why this matters in research context
The 2 mL fill is the standard pick because it keeps the lowest typical dose (100 mcg) at 2 syringe units — well above the precision floor for the 1 mL insulin syringe. Lower-volume fills push the lowest dose to 1 unit, where draw precision becomes the limiting factor. For protocols anchored to the 200-300 mcg dose tier, either fill volume works.
Related compounds
- CJC-1295 No DAC 10mg — the compound covered by this answer
- CJC-1295 + Ipamorelin Blend — combined-formulation; similar reconstitution math at vial level
Related research questions
- What is the half-life of CJC-1295 No DAC?
- Can CJC-1295 be stacked with ipamorelin?
- What is the difference between CJC-1295 with and without DAC?
References
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. CJC-1295 No DAC is sold strictly as a research-grade reagent for laboratory and bench research applications.